23:03 , Jul 11, 2019 |  BC Extra  |  Preclinical News

Elicio's cancer vaccine boosts CAR Ts for solid tumors

The MIT group behind cancer start-up Elicio reported that its technology for boosting immune responses to cancer vaccines can also prime CAR T cells to kill solid tumors. CAR T cell therapies have been approved...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
21:53 , May 31, 2019 |  BC Extra  |  Company News

Bio Palette deal expands Beam's base editing toolbox, Japan strategy

Genome editing companies Beam and Bio Palette announced a cross-licensing deal Friday that grants each biotech access to the other's base editing technologies. The deal also signals Beam is looking for additional opportunities in Japan,...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:15 , May 10, 2019 |  BC Extra  |  Financial News

New Eisai venture arm to focus on digital tech, dementia, cancer

As Eisai looks to digital technologies for dementia drug discovery, the Japanese pharma’s newly launched venture arm has made its first investment and backed Tokyo-based digital healthcare company Allm. Eisai Co. Ltd. (Tokyo:4523) said the...
22:02 , Apr 15, 2019 |  BC Extra  |  Company News

Gelesis' weight loss aid gains U.S. approval

Gelesis said Sunday it received FDA clearance for Plenity (Gelesis100), making the prescription weight loss product available to patients who are ineligible for gastric bypass surgery. Plenity is indicated for use as an aid in...
23:07 , Mar 25, 2019 |  BC Extra  |  Financial News

Biogen announces $5B stock buyback on heels of Alzheimer’s hit

For the second time in a year, Biogen has announced a share repurchase program on the heels of bad news from an Alzheimer's candidate. This time, the big biotech has authorized the repurchase of $5...
00:07 , Mar 7, 2019 |  BC Extra  |  Preclinical News

STING structures reveal target sites

A trio of papers co-led by Zhijian “James” Chen revealed the molecular structure of STING in complex with two factors in its signaling pathway and a new function -- autophagy induction. The findings, reported in...
19:26 , Mar 1, 2019 |  BioCentury  |  Emerging Company Profile

Siolta: Seeding the microbiome

Backed by Khosla Ventures and about a decade of research connecting the microbiome to allergic diseases, Siolta Therapeutics Inc. has its bacterial cocktail in a Phase I trial to prevent the onset of asthma in...
21:58 , Feb 21, 2019 |  BC Extra  |  Preclinical News

Repurposing an HIV target could aid brain injury recovery

Extending CCR5 inhibition beyond treating HIV/AIDS, UCLA researchers showed that blocking CCR5 could promote recovery from stroke and traumatic brain injury (TBI). CC chemokine receptor 5 (CCR5; CD195) is well known for its role in...